Radiant Insights, IncRadiant Insights has announced the addition of “Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate, Feiba), By Type of Hemophilia, By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement, Immune Tolerance Induction) Outlook 2022" Market Research report to their database.
Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged bleeding due to the lack of factors required for the clotting of blood. According to World Federation of Hemophilia, about one in 10,000 people are born with this disease. Various types of drugs are injected into the veins of patient in order to replace the clotting factors, which are missing or low in number.
Request for Free Sample at: https://www.radiantinsights.com/research/global-hemophilia-therapeutics-market/request-sample
As per Radiant Insights report “Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate, Feiba), By Type of Hemophilia, By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement, Immune Tolerance Induction) Outlook 2022”, the global hemophilia therapeutics market is anticipated to witness a moderate growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global hemophilia therapeutics market. The report provides insight about the major drivers, such as increasing awareness about hemophilia and its treatment options, grants and tax credits, for the global hemophilia therapeutics market. Furthermore, few challenges, such as manufacturing difficulties and low switching rate between hemophilia medicines, which are hindering the growth of the global hemophilia therapeutics market have also been mentioned in the report. In addition, the report also highlights various opportunities available for growth of the global hemophilia therapeutics market.
The global hemophilia therapeutics market has been segmented on the basis of type of hemophilia, i.e. Hemophilia A, Hemophilia B, and Others. Hemophilia A occupies the largest share in the global hemophilia therapeutics market, owing to the highest prevalence of this type of hemophilia. Moreover, strong pipeline of drugs for Hemophilia A is also helping its market to grow all across the globe.
Furthermore, the global hemophilia therapeutics market has also been segmented on the basis of type of treatment. According to the report, the treatment for hemophilia can either be an on-demand treatment or a prophylaxis treatment. Currently, on-demand treatment dominates the global hemophilia therapeutics market, as patients usually go for treatment only when bleeding episodes occur. However, prophylaxis is forecasted to be the fastest growing segment owing to the requirement of better management of bleeding episodes.
Full Research Report On Global Hemophilia Therapeutics Market Analysis available at: https://www.radiantinsights.com/research/global-hemophilia-therapeutics-market
Similarly, the market has also been segmented on the basis of type of therapy into replacement therapy and immune tolerance induction therapy. Apart from these types of therapies, efforts are also being made by various pharmaceutical and biotech companies to develop gene therapy for the treatment of hemophilia. Gene therapy is an evolving field which focuses on correcting defective genes in order to cure genetic diseases, such as hemophilia. Use of gene therapy for hemophilia treatment is a promising option, as hemophilia is caused due to a single genetic defect. Even a minimal success from this procedure can mean significant improvement in quality of life for patients. Numerous companies, such as BioMarin Pharmaceuticals and uniQure, are carrying out clinical trials for gene therapies for the treatment of hemophilia. Hence, gene therapy presents great opportunities for the growth of global hemophilia therapeutics market in the coming years.
Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America accounted for the largest share in the global hemophilia therapeutics market. Moreover, the report also highlights various mergers and acquisitions taking place in the global hemophilia therapeutics industry. The pipeline of hemophilia drugs have also been mentioned in the report.
The last section of the report discusses about the prominent players in global hemophilia therapeutics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and product pipeline. The recent developments of every player have also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global hemophilia therapeutics market.
Browse reports of similar category available with Radiant Insights, Inc.:
• DNA Vaccine Market :- https://www.radiantinsights.com/research/global-dna-vaccine-market-outlook-2022
• Live Cell Imaging Market:- https://www.radiantinsights.com/research/live-cell-imaging-market-outlook-2022
Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist - USA
Email: Send Email
Phone: (415) 349-0054, Toll Free: 1-888-928-9744
Address:201 Spear Street 1100, Suite 3036
City: San Francisco
State: CA
Country: United States
Website: www.radiantinsights.com/research/global-hemophilia-therapeutics-market
Source: www.abnewswire.com
